$PCOR

Courtemanche Craig F. Jr. sold $2.5M of PCOR

Courtemanche Craig F. Jr. sold 56,122 shares of PROCORE TECHNOLOGIES, INC. (PCOR) at an average of $45.14 ($44.69–$45.29, $2.53M total) across 2 trades on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Courtemanche Craig F. Jr.
Published Jun 13, 2026, 1:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 13, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PCOR
Neutral
medium confidence
Mentioned
$PCOR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCORNeutralLow
01

Why it matters

The disclosure updates the insider’s holdings (919,704 shares after sale) but does not provide new company performance, guidance, or deal information.

02

Market read

Primarily a sentiment/positioning datapoint; likely low incremental trading value absent other catalysts.

03

What to watch

Traders may overreact to insider sales; the key mitigating factor here is the pre-arranged 10b5-1 structure, which often makes the timing less informative.

Relevance 5/10Novelty 2/10Timing: Filed 2026-06-12 for a 2026-06-10 sale

Background

The article is an SEC Form 4 disclosure of an insider’s open-market sale by a director of Procore Technologies.

Company-level read

Ticker impact

$PCORNeutralMedium confidence
Context

Director Courtemanche Craig F. Jr. sold 56,122 shares of Procore Technologies in open-market trades under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any effect is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider sale with an explicit pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider transaction data with no stated operational/regulatory catalyst.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, the sale size could reflect personal liquidity needs without implying bearish fundamentals; price impact may be negligible.

Key entities

  • PROCORE TECHNOLOGIES, INC.

    Subject of the Form 4 insider transaction; director sold shares under a 10b5-1 plan.

  • Courtemanche Craig F. Jr.

    Director who executed the open-market sale of 56,122 shares on 2026-06-10.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PCORMed

Citizens raises Procore stock price target to $77 on customer feedback

Citizens raised its price target for Procore (NYSE:PCOR) to $77 from $71, maintaining a Market Outperform rating. The increase follows customer feedback and due diligence at the company's conference. Procore's stock is down 13% year-to-date but up 8.6% in the past week. Analysts have mixed views, with targets ranging from $55 to $88. Procore's Q3 2026 earnings are due November 3.

$PCORMed

Procore Technologies (PCOR) Gets A Fresh Look On Zacks Upgrade As Undervalued Narrative Holds

Procore Technologies (PCOR) was upgraded to a Zacks Rank #2 rating, highlighting its earnings outlook. The stock has shown mixed performance, with a 24.75% 90-day return but a 13.49% YTD decline. Analysts estimate a fair value of $69.32, suggesting a 12.6% undervaluation. The company's expansion and cross-selling initiatives are noted as growth drivers, but macro headwinds and competition pose risks. PCOR trades at 6.5x sales, a premium to the sector.